Expression of DLL3 is known to be a feature of pulmonary high-grade small-cell and large-cell neuroendocrine carcinomas and high-grade prostate neuroendocrine carcinomas as well as other neuroendocrine neoplasms [4–6]. Here, DLL3 is linked to prostate neuroendocrine neoplasm.